CRUSHing Lab Fraud: Three Myths that Derail Real Reform

Leeza Osipenko Ekaterina Cleary Julie Egginton By JULIE EGGINGTON, EKATERINA CLEARY & LEEZA OSIPENKO When CMS issued its Request for Information under the Comprehensive Regulations to Uncover Suspicious Healthcare (CRUSH) initiative in February, it zeroed in on a long-festering problem: fraud, waste, and abuse in laboratory testing, especially in genetic and molecular diagnostics. The laboratory…

Read More

Does biosimilar entry reduce cost for patients?

Biosimilars aim to be lower cost options for biologic therapies after loss of exclusivity. A key question is whether these cost savings get passed through to patients via lower out-of-pocket costs. A paper by Dayer et al. (2026) aims to answer this question using 2011-2023 Merative MarketScan Commercial claims data. The authors observed: …significant patient…

Read More

Bribery, Corruption and the American Health Care Way

These days you just have to wonder about the greed and corruption that is going on all around. Senator Dick Blumenthal is one of many who’ve been pointing out the naked corruption in the Trump family–Qatari jets, memecoins, Trump’s son being on the board of so many defence and prediction market companies you can’t keep…

Read More

Are drug prices value-based?

One of the central tensions in pharmaceutical policy is the gap between what a drug is worth and what it actually costs. In theory, a drug’s price should reflect its value — its ability to improve health outcomes relative to the next best alternative. In practice, list prices are set by manufacturers, net prices are shaped by opaque…

Read More